Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review

Table 2

Hazard ratios (HRs) with 95% confidence intervals (CIs) for progression-free survival (PFS) and overall survival (OS).

Author (year)	PFS HR (95% CI)			OS HR (95% CI)
	KIT exon 9 versus KIT exon 11	KIT exon 9 versus WT	KIT exon 11 versus WT	KIT exon 9 versus KIT exon 11	KIT exon 9 versus WT	KIT exon 11 versus WT
Heinrich et al. (2008) [7]	0.59 (0.30–1.16)	0.56 (0.24–1.26)	2.01 (0.85–4.74)	0.36 (0.19–0.68)	0.83 (0.22–3.11)	1.42 (0.50–4.01)
Chen et al. (2011) [15]	2.31 (0.64–8.32)	NA	NA	1.37 (0.35–5.42)	NA	NA
Koh et al. (2011) [16]	NA	NA	0.57 (0.07–4.28)	NA	NA	NA
Li et al. (2012) [17]	0.34 (0.02–6.42)	0.41 (0.02–4.31)	0.59 (0.22–1.59)	NA	NA	NA
Rutkowski et al. (2012) [18]	NA	NA	NA	0.82 (0.33–2.07)	0.73 (0.14–3.79)	1.43 (0.49–4.21)
Yoon et al. (2012) [19]	NA	NA	NA	1.55 (0.74–3.24)	0.85 (0.29–2.48)	0.84 (0.41–1.72)
Reichardt et al. (2016) [20]	0.59 (0.39–0.89)	NA	NA	0.55 (0.38–0.80)	NA	NA

NA: not available.